Vaccine & Gene Therapy Institute

VGTI provides lifesaving solutions through transformative biomedical discovery and research, enabling the prevention and cure of global infectious diseases.

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Congratulations to our Streblow, Labriola, DeFilippis, Estes, Axthelm, and Hirsch lab and affiliate lab teams with additional contributors! Last week they published a new joint article related to the Zika virus vaccine. Their paper uses a highly pathogenic nonhuman primate pregnancy model.

Read more at: https://t.co/EF16thT1IV

[OHSU Knight Cancer Institute @OHSUKnight]

“Every time we uncover a new way tumors suppress the immune system, we gain another opportunity to fight back. That's how better treatments are built.”

- Dr. Robert Eil (@surgeonscie) on new #OHSUResearch:
https://t.co/F4NBHR59SD

[OHSU @OHSUNews]

#1 in Oregon.

Oregon Health & Science University once again ranks first among the best hospitals in Oregon, according to @usnews & World Report’s Best Hospitals 2026 – 27. https://t.co/SuqIzrFxeO

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

This week our Sacha, Wolters, and Hansen lab and affiliate lab teams with additional contributors including Nancy Haigwood and Ann Hessel, published a new paper in Nature Microbiology! Their findings suggest a synergy between broadly neutralizing antibodies, ART and CCR5 blockade for preventing viral reservoir establishment and offer potential improvements over current therapies for newborns exposed to HIV.

Read the full article at:
https://t.co/PdB2GqbBlw

[OHSU @OHSUNews]

An OHSU-led study suggests a one-time regimen of therapies given to newborns within days of birth could permanently clear HIV, offering a potential alternative to lifelong therapy. #HIV #OHSUResearch https://t.co/uYcfzWXAvk

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Please join us in congratulating Associate Professor Alec Hirsch, Ph.D., on his new grant award with National Institute of Allergy & Infectious Disease! His work will focus on a mechanistic analysis of combined liposome- TLR7/7 agonist adjuvanted virus-like particle vaccine.

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Congratulations to our Hancock, Streblow, and Caposio lab teams and their contributors! Their paper explores the UL22A protein and the UL22A Y65 and Y69 residues, and how they're necessary for efficient HCMV reactivation from latency in CD34+ hematopoietic progenitor cells. And that UL22A expression is essential for reactivation in a humanized mouse model.

Read more at: https://t.co/sHnwMdPbgb

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Please join us in congratulating our Bimber, Hansen, Labriola, Axthelm, and Picker labs and affiliate lab teams with their contributors, on their publication in Frontiers Immunology! Their paper uses T Cell Antigenic Recognition Sequencing (TAR-seq) to provide a precise and comprehensive characterization of the differentiation state and functional response of T cells specific to a given antigen, ex vivo and in vivo.

Read more at:
https://t.co/YuxAGEb9Yq

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

O'nyong-nyong virus (ONNV) is a mosquito-borne alphavirus first isolated in 1959. Currently, we have a limited understanding of ONNV infection and disease in relevant animal models, which restricts the evaluation of vaccines and therapeutics. Our Streblow, Axthelm, and Labriola lab and affiliate lab teams with their contributors, are currently investigating with ONNV0804 and the immune responses to alphaviruses and evaluating vaccines to protect against future epidemics.

Read more at:
https://t.co/2XvIkELxXw

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Congratulations to Associate Professor Rebecca Skalsky, Ph.D., on her new paper! Her review looks at common themes for both human and viral miRNAs in viral infection processes, which highlights their dual functions in suppressing and promoting viral life cycles.

Read more by visiting:
https://t.co/AaDwhKp0fP

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

We are happy to celebrate our Wilder Lab Team on their feature article in OHSU News! They are hard at work researching a universal vaccine against malaria. Great job everyone!

Read more by visiting OHSU news:
https://t.co/vXYfNNEPbQ

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Celebrating our newest faculty member Emily Voigt, Ph.D., on recieving the OCTRI Biodmedical Innovation Drug Award! Congratulations Emily 🎉

Her work will focus on an NLC-Delivered saRNA vaccine for Respiratory Syncytial Virus.

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Great work Wilder Lab Team!

[OHSU @OHSUNews]

“This publication opens an entirely new era for malaria vaccines previously impossible without these key data.” https://t.co/Srs0lhYxDy #OHSUResearch #Malaria #Vaccines

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Congratulations to our Wilder lab team for securing a new grant award!

Their work will focus on developing a heterologous vesicular stomatitis virus prime-virus vesicle boost vaccine regimen for Malaria, that can generate a protective cellular and humoral immunity to multiple antigens present at multiple stages of the parasite life cycle.

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Please join us in celebrating Caralyn Labriola, BVMS DACVP, and her lab team, on receiving a grant from the Collins Medical Trust! 🎉

This study will examine the translational characteristics of the nasopharyngeal lymphatic plexus (NPLP) across humans and non-human primates (NHP) at the anatomic, cellular, and molecular level.

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Congratulations to our Wilder lab team, and contributors, on their recent publication! Currently, both licensed Malaria vaccines target only the circumsporozoite protein expressed during early stages of Plasmodium falciparum infection. These results provide the proof-of-concept evidence that multi-stage antibodies may be more protective compared to a single stage approach.

Read the full article here:
https://t.co/AGKTPIW7bM

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Amazing news to share today— OHSU VGTI Professor Scott Hansen, Ph.D, receives a promotion to Quality and Operations Lead for the University Shared Resources (USR)! 🎉🥳 Congratulations Scott!

[Vaccine & Gene Therapy Institute @VGTI_OHSU]

Congratulating Professor Scott Hansen, Ph.D., and his lab team, who have been awarded a $210,000 grant from the National Institute of Allergy and Infectious Diseases!

This is part of the larger award from National Institutes of Health on March 6, 2026, to support research evaluating a prototype tuberculosis vaccine.